Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025

Wave Life Sciences Ltd.

2024-Q2 EPS reported -$0.50 revenue$32,230,000

Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.
SELECT-HD: WVE-003 reduced mutant HTT up to 46%, statistically significant; slowing caudate atrophy; Takeda opt-in submitted.
DMD: FORWARD-53 dystrophin data expected 3Q2024; WVE-N531 previously showed 53% exon skipping.
AATD: RestorAATion-2 dosing initiated; proof-of-mechanism data expected 4Q2024.
Obesity: WVE-007 FIH study expected Q1 2025; preclinical data at R&D Day Fall 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.